Patent · US Active

Polymorphic forms of metopimazine

US10836757B1 · kind B1 · utility

1Cited by
39References
24Claims
0Family size

Assignee

Inventor

  • Shu Yu · Xiangcheng District, CN

Key dates

Filing dateApr 2, 2020
Grant dateNov 17, 2020
Priority date—
Expiry dateApr 2, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07B2200/13
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Provided herein are novel polymorphic forms of metopimazine mesylate. These polymorphic forms are useful in methods, compositions, and kits for the treatment of an enteric nervous system disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.